Rezolute, Inc. (NASDAQ: RZLT) is one of the most closely watched biotech movers heading into the Dec. 12, 2025 session after a pivotal clinical trial miss triggered a historic repricing of the stock. As of the latest available trading update on Friday, December 12, 2025, Rezolute shares are trading around $1.40, down roughly $9.55 versus the prior close—about an 87% one-day collapse that has reset expectations across Wall Street.
This article covers what happened, why it matters, where sell-side forecasts now stand (as of 12/12/2025), and what catalysts could still move Rezolute stock next.
What happened to Rezolute stock: the Phase 3 sunRIZE readout
On December 11, 2025, Rezolute reported topline results from sunRIZE, its Phase 3 trial evaluating ersodetug in congenital hyperinsulinism (HI)—a rare condition linked to dangerous hypoglycemia (low blood sugar), often affecting children.
The headline: sunRIZE did not meet its primary or key secondary endpoint.
The key efficacy numbers investors are reacting to
Rezolute disclosed that:
- Primary endpoint (self-monitored blood glucose): at the top dose (10 mg/kg), ersodetug produced an ~45% reduction in weekly hypoglycemia events—but this was not statistically significant versus placebo, where patients saw an ~40% improvement.
- Key secondary endpoint (continuous glucose monitoring): the top dose showed an ~25% reduction in time spent in hypoglycemia, versus placebo where time in hypoglycemia increased ~5%—again not statistically significant.
The trial enrolled 63 participants ages 3 months to 45 years in more than a dozen countries, including U.S. patients.
Safety: generally favorable, but hypersensitivity reactions noted
Rezolute said safety observations were generally favorable, but reported two serious hypersensitivity reactions that led to early discontinuation of study drug. The most commonly reported adverse event versus placebo was hypertrichosis (generally mild/self-limiting).
Why the miss hit so hard: placebo response and a “binary” biotech setup
The violent move in RZLT stock reflects how “binary” late-stage biotech catalysts can be—especially when a company is essentially anchored to one lead asset.
Reuters reported that CEO Nevan Elam attributed the unusually strong placebo response to the reality of running trials in ultra-rare pediatric populations, where families may intensively manage glucose levels during the study—potentially narrowing the measured separation between drug and placebo.
Industry coverage echoed that the company had been staffing up for commercialization before this readout, underscoring how much optimism had been priced into Rezolute shares ahead of data.
Rezolute’s response: FDA meeting planned under Breakthrough Therapy Designation
Despite the miss, Rezolute has not fully closed the door on congenital HI. In its release, management said it is conducting a deeper evaluation of the outcomes and intends to meet with the FDA under its Breakthrough Therapy Designation to consider next steps.
Reuters also highlighted that more than 50 children from the trial are continuing on drug in an extension study, with some reportedly weaned off other background therapies—details that could become important if the company tries to identify subgroups or alternative approaches for a regulatory path.
Rezolute stock forecast: analyst targets and rating changes as of Dec. 12, 2025
A major part of today’s (12/12/2025) story is the rapid analyst reset following the Phase 3 failure. In the last 24–36 hours, multiple firms slashed targets and/or downgraded the stock—often while keeping an eye on Rezolute’s remaining Phase 3 program in tumor hyperinsulinism.
Below are notable, widely circulated changes tied to this event:
Price target cuts (and what analysts are keying on)
- H.C. Wainwright: cut its target to $5 from $14, while maintaining a Buy rating. The note emphasized the sunRIZE miss and discussed the view that Rezolute’s cash could still be sufficient to complete the tumor HI program, which uses endpoints considered less prone to behavioral confounders.
- BTIG: lowered its target to $5 from $17 and maintained Buy, while “conservatively” removing congenital HI from its model and trimming tumor HI probability of success (reported to 65% from 70%). TipRanks+1
- Guggenheim: lowered its target to $6 from $15 after the trial failure (per published recap coverage).
Downgrades and more cautious stances
- Craig-Hallum: downgraded Rezolute to Hold from Buy with a $2 price target after the Phase 3 miss.
- Wedbush: downgraded to Neutral from Outperform and cut its target to $1 (from $12), citing the negative top-line data; one recap noted Wedbush removed both congenital and tumor hyperinsulinism programs from its valuation despite management’s continued confidence in upLIFT.
- Cantor Fitzgerald: cut Rezolute from Overweight to Neutral, according to MarketBeat’s compilation of analyst actions.
- Citigroup: downgraded from Outperform to Market Perform (again reflected in MarketBeat’s roundup).
A note on “consensus” targets right now
Some widely displayed “consensus target prices” may still reflect pre-readout assumptions and can lag fast-moving situations. For example, MarketBeat still displayed an average target in the low teens and a “Moderate Buy” consensus in its post-event coverage—data that may take time to fully incorporate all post-sunRIZE revisions. MarketBeat+1
What’s left in the story: Rezolute’s tumor hyperinsulinism program (upLIFT)
After sunRIZE, investors are refocusing on whether Rezolute can still create value through its tumor hyperinsulinism opportunity.
Rezolute positions ersodetug as a fully human monoclonal antibody that binds allosterically to the insulin receptor and may reduce receptor over-activation by insulin and related substances (including IGF-2), potentially addressing hypoglycemia across different forms of hyperinsulinism.
Timeline: topline data expected in 2H 2026
Rezolute continues to guide that the Phase 3 upLIFT study in tumor HI remains ongoing, with topline results expected in the second half of 2026.
Why upLIFT is viewed differently than sunRIZE
In a prior corporate update (Form 8-K dated Nov. 6, 2025), Rezolute stated it had alignment with the FDA on a streamlined registrational path in tumor HI: a truncated, single-arm, open-label Phase 3 study in up to 16 hospitalized participants, presented as acceptable as an adequate and well-controlled study to support registration.
Rezolute’s pipeline materials also highlight the two Phase 3 programs (congenital and tumor HI) and the topline timing expectations (2H 2026 for tumor HI).
Regulatory tailwinds: Breakthrough Therapy Designations
Rezolute previously announced Breakthrough Therapy Designation for ersodetug in congenital HI (Jan. 2025) and tumor HI (May 2025). These designations are intended to expedite development and review where preliminary evidence suggests meaningful improvement over available therapies.
Balance sheet context: cash, runway questions, and a shelf filing days before the crash
After a drawdown of this magnitude, biotech investors typically scrutinize cash runway and financing risk as much as the science.
Cash and investments (latest disclosed in 2025 filings)
In its Nov. 6, 2025 financial update, Rezolute reported $152.2 million in cash, cash equivalents, and marketable securities as of Sept. 30, 2025 (down from $167.9 million at June 30, 2025).
Shelf registration filed Dec. 5, 2025
On Dec. 5, 2025, Rezolute filed an automatic shelf registration statement (Form S-3) describing the ability to offer, from time to time, multiple types of securities (including common stock, preferred stock, debt securities, warrants, rights, and units). The prospectus also noted that on Dec. 4, 2025, the last reported sale price of Rezolute common stock was $9.70.
A shelf filing doesn’t automatically mean an imminent offering—but after a major clinical miss, the existence of a shelf can become part of the “overhang” narrative as investors weigh potential dilution.
Legal headlines on Dec. 12, 2025: investigations emerge after the selloff
It’s also typical for large single-day drops to trigger headlines from plaintiff law firms announcing investigations. On Dec. 12, 2025, Hagens Berman publicly stated it was investigating Rezolute following the trial failure and the sharp share-price move.
Important context: an “investigation” announcement is not the same as a court finding or a proven claim. But it can still contribute to volatility and uncertainty around the stock in the near term.
What to watch next for Rezolute (RZLT) stock
With congenital HI now under a cloud, the RZLT stock forecast will likely hinge on a handful of high-impact catalysts and decisions:
- FDA discussions on “path forward” for congenital HI
Management explicitly said it intends to meet with FDA under Breakthrough Therapy Designation to consider next steps. Rezolute, Inc. - More detail on why sunRIZE missed
Investors will look for deeper disclosures (subgroup analyses, baseline severity, endpoint sensitivity, site variability, placebo dynamics), and whether any dataset supports another trial design or a narrower label strategy. - upLIFT execution and timeline clarity
Rezolute continues to point to 2H 2026 topline data for tumor HI, which now becomes the lead value driver. - Financing signals
Cash at Sept. 30, 2025 was substantial by small-cap biotech standards, but timelines, trial costs, and strategic pivots matter—especially with an active shelf registration in place.
Bottom line: Rezolute stock is now a high-volatility, catalyst-driven biotech bet
As of Dec. 12, 2025, Rezolute stock has shifted from a late-stage “approval narrative” in congenital HI to a more uncertain story centered on:
- whether the company can salvage some congenital HI path through further analysis and FDA engagement, and
- whether tumor hyperinsulinism (upLIFT) can deliver a cleaner, more persuasive efficacy signal on a registrational endpoint.
